CN102060903B - Ginsenoside Rh2 extractive and preparation method thereof - Google Patents
Ginsenoside Rh2 extractive and preparation method thereof Download PDFInfo
- Publication number
- CN102060903B CN102060903B CN200910228463.2A CN200910228463A CN102060903B CN 102060903 B CN102060903 B CN 102060903B CN 200910228463 A CN200910228463 A CN 200910228463A CN 102060903 B CN102060903 B CN 102060903B
- Authority
- CN
- China
- Prior art keywords
- ethanol
- concentrated
- ginseng
- ginsenoside
- silica gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- CKUVNOCSBYYHIS-UHFFFAOYSA-N (20R)-ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1O CKUVNOCSBYYHIS-UHFFFAOYSA-N 0.000 title claims abstract description 53
- CKUVNOCSBYYHIS-IRFFNABBSA-N (20S)-ginsenoside Rh2 Chemical compound O([C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CKUVNOCSBYYHIS-IRFFNABBSA-N 0.000 title claims abstract description 53
- CKUVNOCSBYYHIS-LGYUXIIVSA-N 20(R)-Ginsenoside Rh2 Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@H]3[C@](C)([C@@]4(C)[C@H]([C@H](O)C3)[C@@H]([C@](O)(CC/C=C(\C)/C)C)CC4)CC2)CC1 CKUVNOCSBYYHIS-LGYUXIIVSA-N 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 148
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 57
- 239000000243 solution Substances 0.000 claims abstract description 45
- 229930182490 saponin Natural products 0.000 claims abstract description 34
- 150000007949 saponins Chemical class 0.000 claims abstract description 34
- 235000017709 saponins Nutrition 0.000 claims abstract description 34
- 238000006243 chemical reaction Methods 0.000 claims abstract description 30
- 239000000463 material Substances 0.000 claims abstract description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000000741 silica gel Substances 0.000 claims abstract description 15
- 229910002027 silica gel Inorganic materials 0.000 claims abstract description 15
- 238000010898 silica gel chromatography Methods 0.000 claims abstract description 15
- 229930182494 ginsenoside Natural products 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000006228 supernatant Substances 0.000 claims abstract description 5
- 239000012530 fluid Substances 0.000 claims abstract description 3
- 238000001556 precipitation Methods 0.000 claims description 48
- 244000131316 Panax pseudoginseng Species 0.000 claims description 45
- 239000000284 extract Substances 0.000 claims description 39
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 38
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 38
- 235000008434 ginseng Nutrition 0.000 claims description 38
- 239000012043 crude product Substances 0.000 claims description 20
- 229930182478 glucoside Natural products 0.000 claims description 20
- 150000008131 glucosides Chemical class 0.000 claims description 20
- 102000006995 beta-Glucosidase Human genes 0.000 claims description 14
- 108010047754 beta-Glucosidase Proteins 0.000 claims description 14
- 238000003809 water extraction Methods 0.000 claims description 14
- 239000008351 acetate buffer Substances 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 10
- 102000011759 adducin Human genes 0.000 claims description 9
- 108010076723 adducin Proteins 0.000 claims description 9
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims description 7
- 239000009759 San-Chi Substances 0.000 claims description 7
- 239000012141 concentrate Substances 0.000 claims description 4
- 239000012467 final product Substances 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 238000013016 damping Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 10
- 239000000203 mixture Substances 0.000 abstract description 10
- 238000002156 mixing Methods 0.000 abstract description 2
- 239000013049 sediment Substances 0.000 abstract 2
- 239000007853 buffer solution Substances 0.000 abstract 1
- 238000000151 deposition Methods 0.000 abstract 1
- 238000007865 diluting Methods 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 description 10
- 239000007788 liquid Substances 0.000 description 9
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- -1 electuary Substances 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 230000000452 restraining effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- MEIRRNXMZYDVDW-MQQKCMAXSA-N (2E,4E)-2,4-hexadien-1-ol Chemical compound C\C=C\C=C\CO MEIRRNXMZYDVDW-MQQKCMAXSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 208000011767 Sarcoma of cervix uteri Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- PODWXQQNRWNDGD-UHFFFAOYSA-L sodium thiosulfate pentahydrate Chemical compound O.O.O.O.O.[Na+].[Na+].[O-]S([S-])(=O)=O PODWXQQNRWNDGD-UHFFFAOYSA-L 0.000 description 1
- NGSFWBMYFKHRBD-UHFFFAOYSA-N sodium;2-hydroxypropanoic acid Chemical compound [Na+].CC(O)C(O)=O NGSFWBMYFKHRBD-UHFFFAOYSA-N 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a Chinese medicine extractive and a preparation method thereof, in particular to a ginsenoside Rh2 extractive and a preparation method thereof. The preparation method of the extractive comprises the following steps of: 1, extracting the medicinal materials containing ginsenosides ingredients with water, depositing the extracting solution in alcohol and collecting supernatant fluid and concentrating to be dry to obtain total saponins; 2, dissolving the total saponins obtained in the step 1 in a buffer solution the PH of which is about 5, reacting by adding Beta-glucosaccharase, diluting a reaction solution after the reaction is finished, and collecting sediment; and 3, dissolving the sediment by ethanol and mixing in silica gel to perform silica gel column chromatography, eluting with a mixture of ethyl acetate and ethanol, collecting fractions rich in ginsenoside Rh2 and concentrating to obtain the ginsenoside Rh2 extractive.
Description
Technical field
The present invention relates to a kind of Chinese medical extract and preparation thereof, particularly ginsenoside Rh2 extract and preparation thereof.
Background technology
Ginseng, aspect treatment cardiovascular and cerebrovascular diseases, has many reports.
Ginseng saponin constituents, can treat coronary heart disease and ishemic stroke.
Ginsenoside Rh2 is the secondary saponin that Ginsenosides produces through hydrolysis, and pharmacodynamic study shows: ginsenoside Rh2 has significant specific restraining effect to the propagation of the cancer cells such as liver cancer, melanin tumour b16, cervical cancer and sarcoma S180.Its mechanism of action is: in cancer cell multiplication process, through ginsenoside Rh2 effect, make cancer cells stop at certain proliferation period, and impel it to reverse as normal cell.
The poor effect of the separated ginsenoside Rh2 of prior art, the inventor is carrying out, in research process, adopting new isolation technique to ginsenoside Rh2 extract, test out one group of new ginsenoside Rh2 extract and preparation method thereof, it is high that the ginsenoside Rh2 extract of preparation has curative effect, and purity is high, good absorption, steady quality, preparation method's separating effect is good simultaneously, and content is high, technique is simple, easy to operate, with low cost, be applicable to suitability for industrialized production.
Summary of the invention
The invention provides a kind of ginsenoside Rh2 extract.
Ginsenoside Rh2 extract of the present invention, preparation method is as follows:
Step 1, the medicinal material water extraction that contains Ginsenosides, extracting solution alcohol precipitation, collects supernatant liquor, is concentrated into dryly, obtains total saponins;
The total saponins that step 2, step 1 obtain is dissolved in the damping fluid of PH5 left and right, adds beta-glucosidase, and reaction, has reacted rear dilute reaction solution, collecting precipitation thing;
Step 3, throw out dissolve with ethanol, admix in silica gel, carries out silica gel column chromatography, with ethanol and ethyl acetate mixed solution, carries out wash-out, collects the stream part of being rich in ginsenoside Rh2, concentrates and get final product;
Wherein described in step 3, ethanol and ethyl acetate mixed solution are the ethyl acetate containing 5-15% ethanol.
Preferred preparation method is as follows:
Step 1, be selected from the medicinal material water extraction that Folium Panacis Quinquefolii, Radix Panacis Quinquefolii, pseudo-ginseng, Sanchi Leaf, ginseng or Ginseng Leaf etc. are contained Ginsenosides, it is 1.05-1.20 that extracting solution is concentrated into relative density, adds ethanol and carries out alcohol precipitation, places, supernatant concentration, to dry, obtains total saponins;
The total saponins that step 2, step 1 obtain is dissolved in the acetate buffer solution of PH5 left and right, adds beta-glucosidase, and reaction, has reacted rear dilute reaction solution, collecting precipitation thing;
Step 3, throw out dissolve with ethanol, admix in silica gel, carries out silica gel column chromatography, by the ethyl acetate containing 5-10% ethanol, carries out wash-out, and thin layer TLC checks wash-out result, collects the stream part of being rich in ginsenoside Rh2, concentrates and get final product.
Preferred preparation method is as follows:
Step 1, be selected from water extraction 2-3 time for medicinal material that Folium Panacis Quinquefolii, Radix Panacis Quinquefolii, pseudo-ginseng, Sanchi Leaf, ginseng or Ginseng Leaf etc. contain Ginsenosides, each 1-2 hour, add the 8-12 times of water yield at every turn, mixed extract, being concentrated into relative density is 1.05-1.20, add 95% ethanol and carry out alcohol precipitation, make to reach 75% containing alcohol amount, more than placing 12h, filter, precipitation solution is concentrated into dry or after decolouring, is concentrated into dryly, obtains total saponins;
The total saponins that step 2, step 1 obtain is dissolved in the acetate buffer solution of PH5 left and right, adds beta-glucosidase, 40 ℃ of reactions, has reacted rear thin up reaction solution and has stirred, and separates out precipitation, and collecting precipitation thing, obtains total secondary ginseng glucoside's crude product;
Step 3, total secondary ginseng glucoside's crude product make to dissolve with ethanol heating, admix in the silica gel of 2 times of amounts, carry out silica gel column chromatography, by the ethyl acetate containing 5-10% ethanol, carry out wash-out, and thin layer TLC checks wash-out result, collects the stream part of being rich in ginsenoside Rh2, concentrated.
The present invention also comprises the application of ginsenoside Rh2 extract in preparing antitumor drug.
The most preferred preparation method of the present invention in embodiments of the present invention.
The present invention also comprises the pharmaceutical composition of preparing with ginsenoside Rh2 extract of the present invention, and described pharmaceutical composition is the pharmaceutical preparation being prepared into as active constituents of medicine with above-mentioned ginsenoside Rh2 extract.
Pharmaceutical composition of the present invention, can contain medicine acceptable carrier as required, and wherein ginsenoside Rh2 extract is as active constituents of medicine, and its shared weight percent in preparation can be 0.1-99.9%, and all the other are medicine acceptable carrier.Pharmaceutical preparations composition of the present invention, exists with unit dosage form, and described unit dosage form refers to the unit of preparation, as every of tablet, and every capsules of capsule, every bottle of oral liquid, every bag of granule, every of injection etc.
Pharmaceutical composition of the present invention can be any pharmaceutically useful formulation, and these formulations comprise: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, suck agent, granule, electuary, pill, powder, paste, sublimed preparation, suspensoid, pulvis, solution, injection, suppository, ointment, plaster, creme, sprays, drops, patch.
Pharmaceutical composition of the present invention, the preparation of its oral administration can contain conventional vehicle, such as tackiness agent, weighting agent, thinner, tablet agent, lubricant, disintegrating agent, tinting material, seasonings and wetting agent, can carry out dressing to tablet if desired.
Applicable weighting agent comprises Mierocrystalline cellulose, mannitol, lactose and other similar weighting agent.Suitable disintegrating agent comprises starch, polyvinylpyrrolidone and starch derivative, for example sodium starch glycollate.Suitable lubricant comprises, for example Magnesium Stearate.The acceptable wetting agent of suitable medicine comprises sodium lauryl sulphate.Can fill by mixing, the method that compressing tablet etc. are conventional is prepared solid oral composition.Repeatedly mix in those compositions that can make active substance be distributed in a large amount of weighting agents of whole use.
The form of oral liquid can be for example water-based or oily suspensions, solution, emulsion, syrup or elixir, or can be a kind of used water before use or the composite drying products of other suitable carrier.This liquid preparation can contain conventional additive, such as suspension agent, for example sorbyl alcohol, syrup, methylcellulose gum, gelatin, Natvosol, carboxymethyl cellulose, aluminium stearate gel or hydrogenation edible-fat, emulsifying agent, for example Yelkin TTS, anhydro sorbitol monooleate or gum arabic; Non-aqueous carrier (they can comprise edible oil), for example Prunus amygdalus oil, fractionated coconut oil, such as oily ester, propylene glycol or the ethanol of the ester of glycerine; Sanitas, for example para hydroxybenzene methyl esters or propylparaben or Sorbic Acid, and if need, can contain conventional flavouring agent or tinting material.
For injection, the liquid unit dosage of preparation contains active substance of the present invention and sterile carrier.According to carrier and concentration, this compound can be suspended or dissolve.The preparation of solution is normally by active substance being dissolved in a kind of carrier, and filter-sterilized before being packed into a kind of suitable bottle or ampoule, then seals.Auxiliary material for example a kind of local anesthetic, sanitas and buffer reagent also can be dissolved in this carrier.In order to improve its stability, can be after packing bottle into, this composition is freezing, and under vacuum, water is removed.
Pharmaceutical composition of the present invention, when being prepared into medicament, optionally add applicable medicine acceptable carrier, described medicine acceptable carrier is selected from: N.F,USP MANNITOL, sorbyl alcohol, Sodium Pyrosulfite, sodium bisulfite, Sulfothiorine, cysteine hydrochloride, Thiovanic acid, methionine(Met), vitamins C, EDETATE SODIUM, Ethylenediaminetetraacetic Acid Calcium Salt, the alkali-metal carbonate of monovalence, acetate, phosphoric acid salt or its aqueous solution, hydrochloric acid, acetic acid, sulfuric acid, phosphoric acid, amino acid, sodium-chlor, Repone K, Sodium.alpha.-hydroxypropionate, Xylitol, maltose, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol, silicon derivative, Mierocrystalline cellulose and derivative thereof, alginate, gelatin, polyvinylpyrrolidone, glycerine, POLYSORBATE 80, agar, calcium carbonate, Calcium hydrogen carbonate, tensio-active agent, polyoxyethylene glycol, cyclodextrin, beta-cyclodextrin, phospholipid material, kaolin, talcum powder, calcium stearate, Magnesium Stearate etc.
Pharmaceutical composition of the present invention is determined usage and dosage according to patient's situation in use, can take every day three times, each 1-20 agent, as: 1-20 bag or grain or sheet, every dose of 1mg-1000mg.
Below data declaration beneficial effect of the present invention by experiment.
Ginsenoside Rh2 injection liquid has obvious restraining effect through pharmacodynamic experiment proof to the multiple transplantation experiments tumour of mouse, and 50,25,12.5mg/kg ginsenoside Rh2 injection liquid all has obvious restraining effect to murine sarcoma (S180), liver cancer A22 (HepA22), ehrlich carcinoma (ESC), lung cancer (Lewis); Ginsenoside Rh2 injection liquid all has obvious enhancement to tumor-bearing mice Peritoneal Macrophage Phagocytosis and humoral immune function, and can significantly improve NK cytoactive, 40mg/kg ginsenoside Rh2 injection liquid both can promote splenocyte pouring to turn, and can obviously improve again interleukin II (IL-2) activity.
Related tests shows, ginsenoside Rh2 extract of the present invention is higher than prior art curative effect, and purity is high, and productive rate is high, good absorption, and steady quality, purposes is novel, and preparation method's technique is simple, easy to operate, with low cost simultaneously, is applicable to suitability for industrialized production.
Embodiment
With bright the present invention specifically, embodiment is for the ease of understanding the present invention below, and the claim not limiting the present invention in any way and core content.
The preparation of embodiment 1 ginsenoside Rh2 extract
Step 1, Folium Panacis Quinquefolii water extraction 2 times, each 2 hours, add 10 times of water yields at every turn, mixed extract, being concentrated into relative density is 1.05-1.20, add 95% ethanol and carry out alcohol precipitation, make to reach 75% containing alcohol amount, more than placing 12h, filter, precipitation solution is concentrated into dry or after decolouring, is concentrated into dryly, obtains total saponins;
The total saponins that step 2, step 1 obtain is dissolved in the acetate buffer solution of PH5 left and right, adds beta-glucosidase, 40 ℃ of reactions, has reacted rear thin up reaction solution and has stirred, and separates out precipitation, and collecting precipitation thing, obtains total secondary ginseng glucoside's crude product;
Step 3, total secondary ginseng glucoside's crude product make to dissolve with ethanol heating, admix in the silica gel of 2 times of amounts, carry out silica gel column chromatography, by the ethyl acetate containing 10% ethanol, carry out wash-out, and thin layer TLC checks wash-out result, collects the stream part of being rich in ginsenoside Rh2, concentrated.
The preparation of embodiment 2 ginsenoside Rh2 extracts
Step 1, Radix Panacis Quinquefolii water extraction 3 times, each 1 hour, add 8 times of water yields at every turn, mixed extract, being concentrated into relative density is 1.05-1.20, add 95% ethanol and carry out alcohol precipitation, make to reach 75% containing alcohol amount, more than placing 12h, filter, precipitation solution is concentrated into dry or after decolouring, is concentrated into dryly, obtains total saponins;
The total saponins that step 2, step 1 obtain is dissolved in the acetate buffer solution of PH5 left and right, adds beta-glucosidase, 40 ℃ of reactions, has reacted rear thin up reaction solution and has stirred, and separates out precipitation, and collecting precipitation thing, obtains total secondary ginseng glucoside's crude product;
Step 3, total secondary ginseng glucoside's crude product make to dissolve with ethanol heating, admix in the silica gel of 2 times of amounts, carry out silica gel column chromatography, by the ethyl acetate containing 5% ethanol, carry out wash-out, and thin layer TLC checks wash-out result, collects the stream part of being rich in ginsenoside Rh2, concentrated.
The preparation of embodiment 3 ginsenoside Rh2 extracts
Step 1, pseudo-ginseng water extraction 2 times, each 3 hours, add 10 times of water yields at every turn, mixed extract, being concentrated into relative density is 1.05-1.20, add 95% ethanol and carry out alcohol precipitation, make to reach 75% containing alcohol amount, more than placing 12h, filter, precipitation solution is concentrated into dry or after decolouring, is concentrated into dryly, obtains total saponins;
The total saponins that step 2, step 1 obtain is dissolved in the acetate buffer solution of PH5 left and right, adds beta-glucosidase, 40 ℃ of reactions, has reacted rear thin up reaction solution and has stirred, and separates out precipitation, and collecting precipitation thing, obtains total secondary ginseng glucoside's crude product;
Step 3, total secondary ginseng glucoside's crude product make to dissolve with ethanol heating, admix in the silica gel of 2 times of amounts, carry out silica gel column chromatography, by the ethyl acetate containing 10% ethanol, carry out wash-out, and thin layer TLC checks wash-out result, collects the stream part of being rich in ginsenoside Rh2, concentrated.
The preparation of embodiment 4 ginsenoside Rh2 extracts
Step 1, Sanchi Leaf water extraction 2 times, each 2 hours, add 12 times of water yields at every turn, mixed extract, being concentrated into relative density is 1.05-1.20, add 95% ethanol and carry out alcohol precipitation, make to reach 75% containing alcohol amount, more than placing 12h, filter, precipitation solution is concentrated into dry or after decolouring, is concentrated into dryly, obtains total saponins;
The total saponins that step 2, step 1 obtain is dissolved in the acetate buffer solution of PH5 left and right, adds beta-glucosidase, 40 ℃ of reactions, has reacted rear thin up reaction solution and has stirred, and separates out precipitation, and collecting precipitation thing, obtains total secondary ginseng glucoside's crude product;
Step 3, total secondary ginseng glucoside's crude product make to dissolve with ethanol heating, admix in the silica gel of 2 times of amounts, carry out silica gel column chromatography, by the ethyl acetate containing 7.5% ethanol, carry out wash-out, and thin layer TLC checks wash-out result, collects the stream part of being rich in ginsenoside Rh2, concentrated.
The preparation of embodiment 5 ginsenoside Rh2 extracts
Step 1, ginseng water extraction 2 times, each 2 hours, add 10 times of water yields, mixed extract, being concentrated into relative density is 1.05-1.20, adds 95% ethanol and carries out alcohol precipitation, makes to reach 75% containing alcohol amount, more than placing 12h, filter, precipitation solution is concentrated into dry or after decolouring, is concentrated into dryly, obtains total saponins;
The total saponins that step 2, step 1 obtain is dissolved in the acetate buffer solution of PH5 left and right, adds beta-glucosidase, 40 ℃ of reactions, has reacted rear thin up reaction solution and has stirred, and separates out precipitation, and collecting precipitation thing, obtains total secondary ginseng glucoside's crude product;
Step 3, total secondary ginseng glucoside's crude product make to dissolve with ethanol heating, admix in the silica gel of 2 times of amounts, carry out silica gel column chromatography, by the ethyl acetate containing 15% ethanol, carry out wash-out, and thin layer TLC checks wash-out result, collects the stream part of being rich in ginsenoside Rh2, concentrated.
The preparation of embodiment 6 ginsenoside Rh2 extracts
Step 1, Ginseng Leaf use water extraction 2 times, each 2 hours, add 10 times of water yields at every turn, mixed extract, being concentrated into relative density is 1.05-1.20, add 95% ethanol and carry out alcohol precipitation, make to reach 75% containing alcohol amount, more than placing 12h, filter, precipitation solution is concentrated into dry or after decolouring, is concentrated into dryly, obtains total saponins;
The total saponins that step 2, step 1 obtain is dissolved in the acetate buffer solution of PH5 left and right, adds beta-glucosidase, 40 ℃ of reactions, has reacted rear thin up reaction solution and has stirred, and separates out precipitation, and collecting precipitation thing, obtains total secondary ginseng glucoside's crude product;
Step 3, total secondary ginseng glucoside's crude product make to dissolve with ethanol heating, admix in the silica gel of 2 times of amounts, carry out silica gel column chromatography, by the ethyl acetate containing 10% ethanol, carry out wash-out, and thin layer TLC checks wash-out result, collects the stream part of being rich in ginsenoside Rh2, concentrated.
The composition of embodiment 7 ginsenoside Rh2 extracts
The ginsenoside Rh2 extract of the present invention of take is active constituents of medicine, according to technology of pharmaceutics routine techniques, is prepared into the pharmaceutical preparations composition of ginsenoside Rh2 extract, as tablet, and capsule, injection etc.
The assay of embodiment 8 ginseng saponin(e of the present invention Rh2 extract:
The ginsenoside Rh2 extract of embodiments of the invention 1, ginsenoside Rh2 content is 40%.
The anti-tumor activity comparison of embodiment 9 ginseng saponin(e of the present invention Rh2 extract
Test divides two groups, the most preferred ginsenoside Rh2 extract of the ginsenoside Rh2 extract obtaining with extracting method of the prior art and the present invention carries out anti-tumor activity contrast, proves that ginsenoside Rh2 extract of the present invention is higher at the upper anti-tumor activity of what knurl mouse such as murine sarcoma (S180), liver cancer A22 (HepA22), ehrlich carcinoma (ESC), lung cancer (Lewis).
Claims (5)
1. a preparation method for ginsenoside Rh2 extract, is characterized in that, step is as follows:
Step 1, the medicinal material water extraction that contains Ginsenosides, extracting solution alcohol precipitation, collects supernatant liquor, is concentrated into dryly, obtains total saponins;
The total saponins that step 2, step 1 obtain is dissolved in pH and, in 5 damping fluid, adds beta-glucosidase, and reaction, has reacted rear dilute reaction solution, collecting precipitation thing;
Step 3, throw out dissolve with ethanol, admix in silica gel, carries out silica gel column chromatography, with ethanol and ethyl acetate mixed solution, carries out wash-out, collects the stream part of being rich in ginsenoside Rh2, concentrates and get final product;
Wherein described in step 3, ethanol and ethyl acetate mixed solution are the ethyl acetate containing 5-15% ethanol.
2. the preparation method of claim 1, is characterized in that, step is as follows:
Step 1, the medicinal material water extraction that contains Ginsenosides, it is 1.05-1.20 that extracting solution is concentrated into relative density, adds ethanol and carries out alcohol precipitation, places, supernatant concentration, to dry, obtains total saponins;
The total saponins that step 2, step 1 obtain is dissolved in pH and, in 5 acetate buffer solution, adds beta-glucosidase, and reaction, has reacted rear dilute reaction solution, collecting precipitation thing;
Step 3, throw out dissolve with ethanol, admix in silica gel, carries out silica gel column chromatography, by the ethyl acetate containing 5-10% ethanol, carries out wash-out, and thin layer TLC checks wash-out result, collects the stream part of being rich in ginsenoside Rh2, concentrates and get final product;
Wherein, described in contain Ginsenosides medicinal material, be selected from: Folium Panacis Quinquefolii, Radix Panacis Quinquefolii, pseudo-ginseng, Sanchi Leaf, ginseng or Ginseng Leaf.
3. the preparation method of claim 1, is characterized in that, step is as follows:
Step 1, medicinal material water extraction 2-3 time that contains Ginsenosides, each 1-2 hour, add the 8-12 times of water yield at every turn, mixed extract, being concentrated into relative density is 1.05-1.20, add 95% ethanol and carry out alcohol precipitation, make to reach 75% containing alcohol amount, more than placing 12h, filter, precipitation solution is concentrated into dry or after decolouring, is concentrated into dryly, obtains total saponins;
The total saponins that step 2, step 1 obtain is dissolved in pH and, in 5 acetate buffer solution, adds beta-glucosidase, 40 ℃ of reactions, has reacted rear thin up reaction solution and has stirred, and separates out precipitation, and collecting precipitation thing, obtains total secondary ginseng glucoside's crude product;
Step 3, total secondary ginseng glucoside's crude product make to dissolve with ethanol heating, admix in the silica gel of 2 times of amounts, carry out silica gel column chromatography, by the ethyl acetate containing 5-10% ethanol, carry out wash-out, and thin layer TLC checks wash-out result, collects the stream part of being rich in ginsenoside Rh2, concentrated;
Wherein, described in contain Ginsenosides medicinal material, be selected from: Folium Panacis Quinquefolii, Radix Panacis Quinquefolii, pseudo-ginseng, Sanchi Leaf, ginseng or Ginseng Leaf.
4. the preparation method of claim 1, is characterized in that, step is as follows:
Step 1, medicinal material water extraction 2 times that contain Ginsenosides, each 2 hours, add 10 times of water yields at every turn, mixed extract, being concentrated into relative density is 1.05-1.20, add 95% ethanol and carry out alcohol precipitation, make to reach 75% containing alcohol amount, more than placing 12h, filter, precipitation solution is concentrated into dry or after decolouring, is concentrated into dryly, obtains total saponins;
The total saponins that step 2, step 1 obtain is dissolved in pH and, in 5 acetate buffer solution, adds beta-glucosidase, 40 ℃ of reactions, has reacted rear thin up reaction solution and has stirred, and separates out precipitation, and collecting precipitation thing, obtains total secondary ginseng glucoside's crude product;
Step 3, total secondary ginseng glucoside's crude product make to dissolve with ethanol heating, admix in the silica gel of 2 times of amounts, carry out silica gel column chromatography, by the ethyl acetate containing 5-10% ethanol, carry out wash-out, and thin layer TLC checks wash-out result, collects the stream part of being rich in ginsenoside Rh2, concentrated;
Wherein, described in contain Ginsenosides medicinal material, be selected from: Folium Panacis Quinquefolii, Radix Panacis Quinquefolii, pseudo-ginseng, Sanchi Leaf, ginseng or Ginseng Leaf.
5. the preparation method of claim 1, is characterized in that, step is as follows:
Step 1, medicinal material water extraction 3 times that contain Ginsenosides, each 1 hour, add 8 times of water yields at every turn, mixed extract, being concentrated into relative density is 1.05-1.20, add 95% ethanol and carry out alcohol precipitation, make to reach 75% containing alcohol amount, more than placing 12h, filter, precipitation solution is concentrated into dry or after decolouring, is concentrated into dryly, obtains total saponins;
The total saponins that step 2, step 1 obtain is dissolved in pH and, in 5 acetate buffer solution, adds beta-glucosidase, 40 ℃ of reactions, has reacted rear thin up reaction solution and has stirred, and separates out precipitation, and collecting precipitation thing, obtains total secondary ginseng glucoside's crude product;
Step 3, total secondary ginseng glucoside's crude product make to dissolve with ethanol heating, admix in the silica gel of 2 times of amounts, carry out silica gel column chromatography, by the ethyl acetate containing 5-10% ethanol, carry out wash-out, and thin layer TLC checks wash-out result, collects the stream part of being rich in ginsenoside Rh2, concentrated;
Wherein, described in contain Ginsenosides medicinal material, be selected from: Folium Panacis Quinquefolii, Radix Panacis Quinquefolii, pseudo-ginseng, Sanchi Leaf, ginseng or Ginseng Leaf.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910228463.2A CN102060903B (en) | 2009-11-17 | 2009-11-17 | Ginsenoside Rh2 extractive and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910228463.2A CN102060903B (en) | 2009-11-17 | 2009-11-17 | Ginsenoside Rh2 extractive and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102060903A CN102060903A (en) | 2011-05-18 |
| CN102060903B true CN102060903B (en) | 2014-01-15 |
Family
ID=43996422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910228463.2A Expired - Fee Related CN102060903B (en) | 2009-11-17 | 2009-11-17 | Ginsenoside Rh2 extractive and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102060903B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104693263B (en) * | 2015-04-01 | 2016-08-24 | 江苏省中医药研究院 | A kind of arasaponin compound with anti-tumor activity and preparation method and application |
| CN106109953A (en) * | 2016-07-11 | 2016-11-16 | 吕其镁 | Treatment and prevention of tumour Chinese medicine preparation and preparation method thereof |
| CN106900856A (en) * | 2017-03-07 | 2017-06-30 | 吉林大学 | The balloonflower root fermented ginseng Yoghourt and its production method of a kind of green |
| CN111349136A (en) * | 2020-01-17 | 2020-06-30 | 朱业君 | Method for extracting high-purity ginsenoside Rh2 |
| CN115843784B (en) * | 2022-12-30 | 2024-04-30 | 广东康盾高新技术产业集团股份公司 | CAR-NK cell preservation solution, preparation method and preservation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101002785A (en) * | 2006-01-19 | 2007-07-25 | 云南天秀植物科技开发有限公司 | Antineoplastic composition, and process for preparing the same |
-
2009
- 2009-11-17 CN CN200910228463.2A patent/CN102060903B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101002785A (en) * | 2006-01-19 | 2007-07-25 | 云南天秀植物科技开发有限公司 | Antineoplastic composition, and process for preparing the same |
Non-Patent Citations (6)
| Title |
|---|
| 吕迪等.酶解产物人参稀有皂苷Rh3的制备与分离.《大连轻工业学院学报》.2005,第24卷(第3期),182-185. |
| 柱层析法在人参皂甙组分分离中的应用;高峰等;《大连轻工业学院学报》;20001231;第19卷(第4期);274-276 * |
| 赵立亚等.酶法生产稀有人参皂甙及其产物成分的分析.《大连轻工业学院学报》.2002,第21卷(第2期),112-115. |
| 酶法生产稀有人参皂甙及其产物成分的分析;赵立亚等;《大连轻工业学院学报》;20020630;第21卷(第2期);112-115 * |
| 酶解产物人参稀有皂苷Rh3的制备与分离;吕迪等;《大连轻工业学院学报》;20050930;第24卷(第3期);182-185 * |
| 高峰等.柱层析法在人参皂甙组分分离中的应用.《大连轻工业学院学报》.2000,第19卷(第4期),274-276. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102060903A (en) | 2011-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102060903B (en) | Ginsenoside Rh2 extractive and preparation method thereof | |
| CN102178956B (en) | Preparation, medical application and composition of 20S-protopanaxadiol beta-cyclodextrin inclusion compound | |
| EP3572088B1 (en) | A panax plant extract and pharmaceutical composition and use thereof | |
| CN102058646B (en) | Ginsenoside rh2 extract and preparation method thereof | |
| CN1210289C (en) | Radde anemone rhizome extract and its prepn process and use | |
| CN102058644B (en) | Ginseng saponin H extract and preparation method thereof | |
| CN103006769B (en) | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| WO2007140681A1 (en) | The use of cucurbitacins or cucurbitacin compositions in preparation of medicaments for raising leukocytes | |
| CN102266452A (en) | Chinese medicinal composition for enhancing anoxia endurance and preparation method and application thereof | |
| CN102058642B (en) | Ginseng saponin extract and preparation method thereof | |
| CN1294912A (en) | Blood sugar reducing compound | |
| CN106008485A (en) | Medicinal composition of glimepiride, and application thereof in biomedicines | |
| CN103360452B (en) | The Synthesis and applications of Muskmelon Base tetracyclic triterpene cucurbitane compound | |
| CN101156882A (en) | Preparation method of pseudo-ginseng protopanoxadiol saponin and its uasage | |
| CN102058647B (en) | Ginseng glycoside H extract and preparation method thereof | |
| CN102058645B (en) | Ginseng glycoside H extractive and preparation method thereof | |
| CN102058643B (en) | Ginseng saponin H extract and preparation method thereof | |
| CN102988478B (en) | Traditional Chinese medicine combination for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| KR101237898B1 (en) | A composition having anti-metastatic effect | |
| CN104447900B (en) | Preparation activity, application and quality control of new compound | |
| CN100546589C (en) | The preparation of caterpillar fungus cephalosporin powder anti-arrhythmia effective part and pharmaceutical preparation thereof | |
| CN103977163B (en) | Medicinal composition with myocardial ischemia resisting effect, preparation method and application thereof | |
| JPS647048B2 (en) | ||
| CN118045096B (en) | Red peony monoterpene compound and application thereof | |
| CN101966214A (en) | Panax notoginseng triol ginsenoside extract and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent for invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Applicant after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Applicant before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: TIANJIN TIANSHILI PHARMACEUTICAL CO., LTD. TO: TASLY PHARMACEUTICAL GROUP CO., LTD. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: 300410 Tianjin city Beichen District Huaihe road and road intersection Dingjiang tianzhijiao Park forensic Center for Intellectual Property Department Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee before: Tasly Pharmaceutical Group Co., Ltd. |
|
| CP03 | Change of name, title or address | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140115 Termination date: 20201117 |